Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target Raised to $54.00 at B. Riley

Supernus Pharmaceuticals (NASDAQ:SUPN) had its price objective raised by research analysts at B. Riley from $50.00 to $54.00 in a research note issued to investors on Thursday, December 28th, Marketbeat reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. B. Riley’s price objective points to a potential upside of 22.31% from the stock’s previous close. B. Riley also issued estimates for Supernus Pharmaceuticals’ Q3 2018 earnings at $0.57 EPS.

SUPN has been the topic of several other research reports. SunTrust Banks reaffirmed a “buy” rating and set a $61.00 target price on shares of Supernus Pharmaceuticals in a report on Friday, November 3rd. Cowen set a $50.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 23rd. Janney Montgomery Scott reissued a “hold” rating and issued a $47.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Jefferies Group reissued a “buy” rating and issued a $51.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Finally, Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 10th. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $49.90.

Shares of Supernus Pharmaceuticals (NASDAQ SUPN) opened at $44.15 on Thursday. Supernus Pharmaceuticals has a 52 week low of $23.10 and a 52 week high of $50.04. The stock has a market cap of $2,293.98, a P/E ratio of 41.65 and a beta of 1.18.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 19.85% and a return on equity of 26.62%. The firm had revenue of $80.40 million for the quarter, compared to analysts’ expectations of $78.74 million. The company’s revenue for the quarter was up 41.5% on a year-over-year basis. analysts expect that Supernus Pharmaceuticals will post 1.07 EPS for the current year.

In other Supernus Pharmaceuticals news, VP Victor Vaughn sold 55,000 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $40.11, for a total value of $2,206,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Gregory S. Patrick sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $43.56, for a total transaction of $2,178,000.00. The disclosure for this sale can be found here. Insiders sold 120,000 shares of company stock valued at $5,014,650 over the last ninety days. Corporate insiders own 6.70% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its stake in shares of Supernus Pharmaceuticals by 0.5% in the second quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock worth $289,962,000 after acquiring an additional 31,331 shares during the period. Vanguard Group Inc. grew its stake in shares of Supernus Pharmaceuticals by 39.1% in the second quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after acquiring an additional 984,200 shares during the period. State Street Corp grew its stake in shares of Supernus Pharmaceuticals by 3.1% in the second quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock worth $60,230,000 after acquiring an additional 42,165 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Supernus Pharmaceuticals by 10.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,268,082 shares of the specialty pharmaceutical company’s stock worth $54,654,000 after acquiring an additional 122,042 shares during the period. Finally, Neumeier Poma Investment Counsel LLC grew its stake in shares of Supernus Pharmaceuticals by 1.6% in the second quarter. Neumeier Poma Investment Counsel LLC now owns 890,740 shares of the specialty pharmaceutical company’s stock worth $38,391,000 after acquiring an additional 14,430 shares during the period. Hedge funds and other institutional investors own 98.22% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/14/b-riley-increases-supernus-pharmaceuticals-supn-price-target-to-54-00.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply